These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

60 related articles for article (PubMed ID: 8618461)

  • 21. Results of triple therapy with interferon-alpha, cytarabine, and homoharringtonine, and the impact of adding imatinib to the treatment sequence in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in early chronic phase.
    O'Brien S; Giles F; Talpaz M; Cortes J; Rios MB; Shan J; Thomas D; Andreeff M; Kornblau S; Faderl S; Garcia-Manero G; White K; Mallard S; Freireich E; Kantarjian HM
    Cancer; 2003 Sep; 98(5):888-93. PubMed ID: 12942553
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Low-dose cytarabine plus aclarubicin for patients with previously untreated acute myeloid leukemia or high-risk myelodysplastic syndrome ineligible for standard-dose cytarabine plus anthracycline.
    Fukushima T; Kawabata H; Sawaki T; Satoh T; Nakamura T; Iwao H; Nakajima A; Sakai T; Miki M; Fujita Y; Tanaka M; Kawanami T; Masaki Y; Okazaki T; Umehara H
    Anticancer Res; 2012 Apr; 32(4):1347-53. PubMed ID: 22493369
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Curative chemotherapy for acute myeloid leukemia: the development of high-dose ara-C from the laboratory to bedside.
    Capizzi RL
    Invest New Drugs; 1996; 14(3):249-56. PubMed ID: 8958179
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Combination of liposomal daunorubicin (DaunoXome), fludarabine, and cytarabine (FLAD) in patients with poor-risk acute leukemia.
    Clavio M; Venturino C; Pierri I; Garrone A; Miglino M; Canepa L; Balleari E; Balocco M; Michelis GL; Ballerini F; Gobbi M
    Ann Hematol; 2004 Nov; 83(11):696-703. PubMed ID: 15322763
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Hematologic improvement and response in elderly AML/RAEB patients treated with valproic acid and low-dose Ara-C.
    Corsetti MT; Salvi F; Perticone S; Baraldi A; De Paoli L; Gatto S; Pietrasanta D; Pini M; Primon V; Zallio F; Tonso A; Alvaro MG; Ciravegna G; Levis A
    Leuk Res; 2011 Aug; 35(8):991-7. PubMed ID: 21474179
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A phase I study of idarubicin dose escalation with amisfostine and high-dose cytarabine in patients with relapsed acute myelogenous leukemia and myelodysplastic syndromes.
    Garcia-Manero G; Faderl S; Giles F; Thomas D; Cortes J; O'Brien S; Davis J; Kantarjian HM; Estey E
    Haematologica; 2002 Aug; 87(8):804-7. PubMed ID: 12161355
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Low-dose cytosine arabinoside (LD-Ara C) treatment in dysmyelopoietic syndromes (DMPS) and acute myelogenous leukemia (AML).
    Jehn U; Göldel N; Vehling-Kaiser U
    Anticancer Res; 1987; 7(3 Pt B):505-8. PubMed ID: 3477124
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dynamics of BCR-ABL mRNA expression in first-line therapy of chronic myelogenous leukemia patients with imatinib or interferon alpha/ara-C.
    Müller MC; Gattermann N; Lahaye T; Deininger MW; Berndt A; Fruehauf S; Neubauer A; Fischer T; Hossfeld DK; Schneller F; Krause SW; Nerl C; Sayer HG; Ottmann OG; Waller C; Aulitzky W; le Coutre P; Freund M; Merx K; Paschka P; König H; Kreil S; Berger U; Gschaidmeier H; Hehlmann R; Hochhaus A
    Leukemia; 2003 Dec; 17(12):2392-400. PubMed ID: 14523462
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Biochemically targeted therapy of refractory leukemia and myeloid blast crisis of chronic granulocytic leukemia with Tiazofurin, a selective blocker of inosine 5'-phosphate dehydrogenase activity.
    Tricot G; Weber G
    Anticancer Res; 1996; 16(6A):3341-7. PubMed ID: 9042309
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prolonged high dose ARA-C infusions in acute leukemia.
    Spriggs DR; Robbins G; Arthur K; Mayer RJ; Kufe D
    Leukemia; 1988 May; 2(5):304-6. PubMed ID: 3287017
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [High-dose cytosine arabinoside treatment of leukemia with special reference to the optimal number of doses].
    Sampi K; Maseki N; Kumai R; Kaneko Y; Sakurai M; Hattori M
    Gan To Kagaku Ryoho; 1989 Aug; 16(8 Pt 1):2595-8. PubMed ID: 2774589
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype.
    Bloomfield CD; Lawrence D; Byrd JC; Carroll A; Pettenati MJ; Tantravahi R; Patil SR; Davey FR; Berg DT; Schiffer CA; Arthur DC; Mayer RJ
    Cancer Res; 1998 Sep; 58(18):4173-9. PubMed ID: 9751631
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Imatinib in combination with cytarabine for the treatment of Philadelphia-positive chronic myelogenous leukemia chronic-phase patients: rationale and design of phase I/II trials.
    Guilhot F; Gardembas M; Rousselot P; Tulliez M; Vigier M; Buzyn A; Rigal-Huguet F; Legros L; Michallet M; Berthou C; Najman A; Maloisel F; Mahon FX; Facon T; Berthaud P; Guilhot J;
    Semin Hematol; 2003 Apr; 40(2 Suppl 2):92-7. PubMed ID: 12783382
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phase I study of cladribine, cytarabine (Ara-C), granulocyte colony stimulating factor (G-CSF) (CLAG Regimen) and simultaneous escalating doses of imatinib mesylate (Gleevec) in relapsed/refractory AML.
    Walker AR; Komrokji RS; Ifthikharuddin J; Messina P; Mulford D; Becker M; Friedberg J; Oliva J; Phillips G; Liesveld JL; Abboud C
    Leuk Res; 2008 Dec; 32(12):1830-6. PubMed ID: 18571721
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Therapy of refractory/relapsed acute leukemia with cytosine arabinoside plus tetrahydrouridine (an inhibitor of cytidine deaminase)--a pilot study.
    Kreis W; Budman DR; Chan K; Allen SL; Schulman P; Lichtman S; Weiselberg L; Schuster M; Freeman J; Akerman S
    Leukemia; 1991 Nov; 5(11):991-8. PubMed ID: 1961042
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Phase II study of SM-108 (4-carbamoylimidazolium-5-olate) in hematological malignancies].
    Kimura K; Yamada K; Uzuka Y; Masaoka T; Hirano M; Ohno R; Ogawa M
    Gan To Kagaku Ryoho; 1989 Jan; 16(1):123-30. PubMed ID: 2643392
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phase I study of GTI-2040, a ribonucleotide reductase antisense, with high dose cytarabine in patients with relapsed/refractory acute myeloid leukemia.
    Klisovic RB; Blum W; Liu Z; Xie Z; Kefauver C; Huynh L; Zwiebel JA; Devine SM; Byrd JC; Grever MR; Chan KK; Marcucci G
    Leuk Lymphoma; 2014 Jun; 55(6):1332-6. PubMed ID: 24015841
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Risk factors for high-dose cytarabine neurotoxicity: an analysis of a cancer and leukemia group B trial in patients with acute myeloid leukemia.
    Rubin EH; Andersen JW; Berg DT; Schiffer CA; Mayer RJ; Stone RM
    J Clin Oncol; 1992 Jun; 10(6):948-53. PubMed ID: 1588374
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cerebellar toxicity due to cytarabine: A series of 4 cases.
    Sainz de la Maza Cantero S; Jiménez Martín A; de Felipe Mimbrera A; Corral Corral Í
    Neurologia; 2016 Sep; 31(7):491-2. PubMed ID: 25728956
    [No Abstract]   [Full Text] [Related]  

  • 40. [Ara-C].
    Onozawa M; Teshima T
    Nihon Rinsho; 2015 Feb; 73 Suppl 2():623-7. PubMed ID: 25831835
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.